The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.

CONCLUSION: Nivolumab plus ipilimumab represent the most promising immunotherapy combination for the treatment of advanced NSCLC patients; safety, tolerability and efficacy of new immune modulators (in monotherapy and in immune combinations) must be further assessed in future studies. PMID: 31400270 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31400270?dopt=Abstract

Source: Current Clinical Pharmacology - August 8, 2019 Category: Drugs & Pharmacology Authors: Rocco D, Gravara LD, Gridelli C Tags: Curr Clin Pharmacol Source Type: research